Continued capital market volatility, coupled with a costly, tightening, and oftentimes burdensome debt landscape, has driven royalty monetization transactions into the mainstream as life sciences ...
Nathan Moore, Emily Powers, George Shuster Jr. Sustained market conditions have created challenges for many life sciences companies to raise equity capital at attractive pricing, as venture investment ...
NEW YORK and CAMBRIDGE, Mass., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it has acquired a royalty interest in Alnylam’s AMVUTTRA from funds managed by ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback